Acadia Pharmaceutica (ACAD) Stock Price, Quote & News

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 2871

Fax: 858 212 0513

Website: www.acadia.com

Address:

12830 El Camino Real, Suite 400, San Diego, United States

Timothy1267 Aug. 16 at 12:28 AM

$ACAD

0 · Reply

zeustony88 Aug. 15 at 2:42 PM

$ACAD Need a Friday $1-$2 breakout in the worst way

1 · Reply

zeustony88 Aug. 15 at 1:51 PM

$ACAD If you bought on yesterday's dip......

0 · Reply

JustBio24 Aug. 14 at 3:35 PM

$IXHL I am seeing folks worried and anxious about manipulation. If anyone had been investing in $ACAD since 2012-2013, you would have known about manipulation till the last year. Now look where it is. Patience is the only key and perhaps the best defense.

1 · Reply

Quantumup Aug. 14 at 12:41 PM

Cantor reiterated $AARD Overweight/$50 - gives P3 PoS of 65% (partially due to "super-responders"), whereas current valuation implies only 5%. $SLNO $RYTM $ACAD Cantor said: $AARD's valuation implies perhaps a 5% chance of success in the P3 study. We think odds of success are closer to 65%+ - in part driven by some very compelling anecdotes of 'super-responders' which seem very unlikely to be a result of a placebo effect.

0 · Reply

JarvisFlow Aug. 13 at 5:00 AM

Mizuho updates rating for ACADIA Pharmaceuticals ( $ACAD ) to Neutral, target set at 21 → 20.

1 · Reply

raylin Aug. 13 at 1:00 AM

$ACAD Several weeks ago someone posted here about Bakers making a change to their shares - a way to sell them all together or something - that led to speculation it was to make a sale easier. May have been hopium as nothing like that occurred in the three BOs I’ve been in that I’m aware of. However, a BO theory has more legs recently with the patent resolved, new CEO, stronger pipeline, having two approved drugs, etc.

1 · Reply

LoganFive Aug. 12 at 8:10 PM

$ACAD Solid Day 👍🏻

0 · Reply

SBL71 Aug. 12 at 6:35 PM

$ACAD

0 · Reply

Doozio Aug. 12 at 5:45 PM

$ACAD they won’t EXEL bahhhht many will 🐒🍌🧠⏰♾️

0 · Reply

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 3:57 AM EDT - 8 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 9 days ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 5, 2025, 4:05 PM EDT - 10 days ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 4, 2025, 4:05 PM EDT - 11 days ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Jul 28, 2025, 4:32 AM EDT - 18 days ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 23, 2025, 4:05 PM EDT - 23 days ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jun 25, 2025, 8:00 AM EDT - 7 weeks ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 9, 2025, 4:01 PM EDT - 2 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 5, 2025, 9:05 AM EDT - 2 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

May 29, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 19, 2025, 8:25 AM EDT - 3 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 17, 2025, 10:00 AM EDT - 3 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 16, 2025, 1:43 PM EDT - 3 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 13, 2025, 12:01 PM EDT - 3 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 7, 2025, 8:10 PM EDT - 3 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 5, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Apr 23, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Mar 13, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Mar 5, 2025, 9:05 AM EST - 5 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 3, 2025, 9:05 AM EST - 5 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 2, 2025, 5:19 AM EST - 5 months ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Feb 27, 2025, 4:05 PM EST - 6 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 26, 2025, 8:13 PM EST - 6 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 6 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 12, 2025, 4:05 PM EST - 6 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 14, 2025, 9:05 AM EST - 7 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:00 AM EST - 7 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Dec 19, 2024, 4:05 PM EST - 8 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Dec 11, 2024, 4:05 PM EST - 8 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Dec 9, 2024, 9:00 AM EST - 8 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Nov 27, 2024, 3:18 PM EST - 9 months ago

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 26, 2024, 4:05 PM EST - 9 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Nov 11, 2024, 10:50 AM EST - 9 months ago

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 6, 2024, 8:09 PM EST - 10 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 4:05 PM EST - 10 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Nov 5, 2024, 4:05 PM EST - 10 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Oct 17, 2024, 6:41 PM EDT - 10 months ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Oct 16, 2024, 4:07 PM EDT - 10 months ago

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Sep 23, 2024, 4:15 PM EDT - 11 months ago

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Sep 19, 2024, 12:00 PM EDT - 11 months ago

Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals

Aug 26, 2024, 3:02 PM EDT - 1 year ago

Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again

Aug 14, 2024, 8:04 AM EDT - 1 year ago

Ryan Reynolds Announces More to Parkinson's® Campaign

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 6, 2024, 10:15 PM EDT - 1 year ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Jul 18, 2024, 9:04 AM EDT - 1 year ago

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Timothy1267 Aug. 16 at 12:28 AM

$ACAD

0 · Reply

zeustony88 Aug. 15 at 2:42 PM

$ACAD Need a Friday $1-$2 breakout in the worst way

1 · Reply

zeustony88 Aug. 15 at 1:51 PM

$ACAD If you bought on yesterday's dip......

0 · Reply

JustBio24 Aug. 14 at 3:35 PM

1 · Reply

Quantumup Aug. 14 at 12:41 PM

0 · Reply

JarvisFlow Aug. 13 at 5:00 AM

Mizuho updates rating for ACADIA Pharmaceuticals ( $ACAD ) to Neutral, target set at 21 → 20.

1 · Reply

raylin Aug. 13 at 1:00 AM

1 · Reply

LoganFive Aug. 12 at 8:10 PM

$ACAD Solid Day 👍🏻

0 · Reply

SBL71 Aug. 12 at 6:35 PM

$ACAD

0 · Reply

Doozio Aug. 12 at 5:45 PM

$ACAD they won’t EXEL bahhhht many will 🐒🍌🧠⏰♾️

0 · Reply

SanKish Aug. 12 at 5:23 PM

$ACAD 25 crossed. On to 30. I am going for $35 calls, assuming a buyout will put it at around 50-60 range.

0 · Reply

MadMusk Aug. 12 at 5:13 PM

$ACAD 30 coming

0 · Reply

zeustony88 Aug. 12 at 3:45 PM

$ACAD 52 week high and now $26 looking ahead

0 · Reply

zeustony88 Aug. 12 at 1:58 PM

$ACAD Breakout from here and no looking back......

0 · Reply

zeustony88 Aug. 12 at 1:44 PM

$ACAD $ACAD Price Targets Multiple analysts have issued price targets for $ACAD recently. We have seen 18 analysts offer price targets for $ACAD in the last 6 months, with a median target of $28.0. Here are some recent targets: Brian Abrahams from RBC Capital set a target price of $40.0 on 08/07/2025 Uy Ear from Mizuho set a target price of $24.0 on 08/07/2025 Jason N. Butler from JMP Securities set a target price of $35.0 on 08/07/2025 Salveen Richter from Goldman Sachs set a target price of $17.0 on 08/07/2025 Tessa Romero from JP Morgan set a target price of $34.0 on 07/24/2025 Jay Olson from Oppenheimer set a target price of $22.0 on 06/26/2025 Andrew Fein from HC Wainwright & Co. set a target price of $32.0 on 06/26/2025 Can anyone take Goldman Suks for real with that target?

0 · Reply